An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect

Area of Science:

• Ototoxicity and Cancer Therapeutics
• Pharmacology and Drug Development

Background:

• Cisplatin is a vital chemotherapy agent but causes dose-limiting ototoxicity.
• Ototoxicity from cisplatin significantly impacts patient quality of life.
• Src-protein tyrosine kinase inhibitors show promise in other forms of hearing loss.

Purpose of the Study:

• To evaluate a novel Src-protein tyrosine kinase inhibitor for otoprotection against cisplatin.
• To determine if the Src inhibitor compromises cisplatin's antitumor efficacy.
• To assess the compound's safety and effectiveness in preclinical models.

Main Methods:

• Three studies were conducted in rat models (Fischer 344/NHsd and nude rats).
• Cisplatin was administered with or without the Src inhibitor.
• Ototoxicity was measured via auditory brainstem response and outer hair cell counts.
• Antitumor effects were assessed by monitoring tumor volume in nude rats with HT-29 tumors.

Main Results:

• Co-treatment with the Src inhibitor significantly reduced cisplatin-induced hearing loss in two studies.
• The Src inhibitor did not negatively impact cisplatin's tumor growth inhibition in the third study.
• Minimal hearing loss was observed in the third study due to a lower cisplatin dose.

Conclusions:

• The novel Src inhibitor demonstrates significant otoprotective potential against cisplatin.
• This Src inhibitor may offer a strategy to mitigate cisplatin ototoxicity without sacrificing antitumor activity.
• Further research is warranted to explore clinical applications of this Src inhibitor in cancer therapy.